Disclosure: D.C. has applied for a patent on the diagnostic use of BRAF V600E mutant-specific antibody VE1. All terms are being managed by the German Cancer Research Center in accordance with its conflict of interest policies. The other authors do not have conflict of interest to disclose.
BRAF V600E Mutation Is Associated with mTOR Signaling Activation in Glioneuronal Tumors
Article first published online: 11 SEP 2013
© 2013 International Society of Neuropathology
Volume 24, Issue 1, pages 52–66, January 2014
How to Cite
Prabowo, A. S., Iyer, A. M., Veersema, T. J., Anink, J. J., Schouten-van Meeteren, A. Y. N., Spliet, W. G. M., van Rijen, P. C., Ferrier, C. H., Capper, D., Thom, M. and Aronica, E. (2014), BRAF V600E Mutation Is Associated with mTOR Signaling Activation in Glioneuronal Tumors. Brain Pathology, 24: 52–66. doi: 10.1111/bpa.12081
- Issue published online: 18 DEC 2013
- Article first published online: 11 SEP 2013
- Accepted manuscript online: 13 AUG 2013 10:20PM EST
- Manuscript Accepted: 25 JUL 2013
- Manuscript Received: 5 JUN 2013
- National Epilepsy Fund—“Power of the Small”
- Hersenstichting Nederland. Grant Number: 012-12
- KIKA (Stichting Kinderen Kankervrij; AE, AP)
Figure S1. BRAF V600E mutated ganglioglioma (GG): CD34, MHC-II and MHC-I immunoreactivity. A, B. Prominent CD34 immunoreactivity (IR) within the tumor area. C–E. Prominent MHC class II antigen (MHC-II) expression within the tumor area, with IR in microglial cells (arrows in D and E) and occasionally in large dysplastic neurons (arrowhead in E). F, G. Prominent MHC class I antigen (MHC-I) expression within the tumor area, with IR in large dysplastic neurons (arrows in G). Scale bar in (G): A, C, F: 400 μm; B, G: 80 μm; D, E: 40 μm.
Figure S2. BRAF V600E mutated ganglioglioma (GG): pLKB1. A–C. Phosphorylated (p)-LKB1 immunoreactivity (IR) within the tumor area in large dysplastic neurons (arrows in A; B, C); co-localization of pLKB1 with VE1 is shown in the insert in (A). Scale bar in (C): A. 40 μm; B, C. 20 μm.
Figure S3. VE1 immunoreactivity in ganglioglioma (GG) and in control cortex. A. GG with only few VE1-positive dysplastic neurons (arrows and insert). B. Perilesional cortex without VE1 immunoreactivity (IR). Scale bar in (B): A. 80 μm; B. 160 μm.
Figure S4. MHC-I, MHC-II and pS6 immunoreactivity score (IRS) in GGs and DNTs. A. MHC-I (glial/neuronal) and MHC-II IR scores (total score; mean ± SEM) in GGs and DNTs. B. pS6 (glial/neuronal) IR scores (total score; mean ± SEM) in GGs and DNTs (***P < 0.001). Desmoplastic infantile gangliogliomas (DIGs); gangliogliomas (GGs); dysembryoplastic neuroepithelial tumors (DNTs); dysplastic neurons (DN).
Table S1. Criteria to distinguish diffuse DNTs from other DNT types.
Table S2. Correlation of pS6 IRS with clinical data and histological/immunohistochemical features in GGs and DNTs.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.